Eptacog Alfa (rFVIIa) Market Report: Trends, Forecast and Competitive Analysis to 2035

Eptacog Alfa (rFVIIa) Market

The future of the global eptacog alfa (rfviia) market looks promising with opportunities in the congenital hemophilia and acquired hemophilia markets. The global eptacog alfa (rfviia) market is expected to reach an estimated $2.2 billion by 2035 from $1.5 billion in 2027 with a CAGR of 4.1% from 2027 to 2035. The major drivers for this market are the increasing incidence of congenital bleeding disorders, the rising demand for rapid hemostatic agents, and the growing awareness of advanced coagulation therapies.

• Lucintel forecasts that, within the type category, prefilled syringe is expected to witness higher growth over the forecast period due to easy self-administration made possible by pre-filled syringes.
• Within the application category, acquired hemophilia is expected to witness higher growth over the forecast period due to increased cases of acquired hemophilia.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more diagnosis and treatment options for hemophilia.

Emerging Trends in Eptacog Alfa (rFVIIa) Market

Between 2025 and 2027 the market for eptacog alfa (rfviia) will move from hospital-based rescue operations to regulated, indication-specific treatments. According to Lucintel, in the absence of a protocol to manage inhibitors, health care practitioners are conducting research on the feasibility of alternate delivery methods, particularly the subcutaneous route. Further, health care practitioners are evaluating the evidence to support the use of eptacog alfa and other bypassing agents.

• Indication-specific Treatments: Health care practitioners serving the indication of acquired hemophilia, in 2025, were in the process of further defining the patient population. Within the acquired hemophilia indication, a single patient may require multiple treatments.
• Dosing Efficiency: Health care practitioners serving the indication of hemophilia were evaluating the alternative bypassing agents, including eptacog alfa and emicizumab, based on the overall cost and the number of doses.
• Specialist-led Treatment: Emergency treatment for hemophilia is largely centered in regional treatment centers, including multidisciplinary teams. Other health care facilities are developing similar protocols to facilitate transport of patients in hemorrhagic shock.
• Digital Management of Haemophilia: The use of telehealth to manage haemophilia will continue to evolve over the next few years, incorporating the online reporting of bleeds and the management of infusion schedules. This will also enable health care professionals to video conference with patients. Improved real-world data will assist health care professionals to determine when to use the bypassing agent rFVIIa.
• Supply and Access Challenges: The World Federation of Hemophilia's (WFH) 2024 data reported treatment gaps for the majority of the countries in the low and lower-middle income countries. Simultaneously, proactive efforts by some countries and international organizations to ensure reliable and affordable supplies for the targeted years (2025 to 2027) are underway. For companies with products distributed in these regions, the absence of even reimbursement will provide some level of protection.

During the next five years, the most innovative products that improve pharma economics, ease the burden of treatment, and ensure rapid control of bleeding will be prioritized. Though many challenges including the presence of biosimilar products and the constraints of reimbursement will remain, the most favorable markets will be decided by the best, evidence-based, regional marketing strategies.

Recent Developments in the Eptacog Alfa (rFVIIa) Market

During the outlook period, the eptacog alfa (rfviia) market will be active as sponsors secure recombinant capacity and clinicians seek non-factor prophylaxis. Lucintel expects continued demand for eptacog alfa for emergency and peri-operative periods. Regulatory, social and economic factors will impact market share and be more relevant than the size of the pipeline.

• FDA Approval for Qfitlia: The monthly Antithrombin lowering drug Fitusiran (Qfitlia) received FDA approval on 28 March, 2025 for patients with Hemophilia A and B. With the use of Qfitlia, clinicians can avoid the use of bypassing agents for prophylaxis. As a result, demand for eptacog alfa for bleeding and surgery prophylaxis is expected to decline while it will be used for break through bleeding and surgery.
• Market Entrance of Hympavzi: Pfizer's Hympavzi (N9-GP) received approval in the US in 2024 for the prevention of bleeding in patients of Hemophilia A and B with no inhibitors. Wide market adoption of the product shift the focus of the prevention budget and lead to restriction of rFVIIa use to break through bleeding.
• Focus on NovoSeven: The sales of NovoSeven in 2024 was DKK 8.1 billion (Novo Nordisk annual report February 2025) and the company expects continued focus on the product in the coming years. With the entry of other products in the market the expected volume growth of NovoSeven will also decline.
• Six Facts Commercial Contraction: HEMA Biologics and LFB stopped commercialization of Seven fact in the U.S. for 2024. Until further notice, NovoSeven enjoys an exclusive position in the market. Decreased competition has little effect on the number of suppliers. For hospitals, the ability to source the product, as well as, how and when it's stocked becomes of prime concern.
• Access Restrictions for High-cost Therapies: The renewal of Roctavian's authorization in August 2025 put payers' scrutiny on other high cost therapies in hemophilia. While budget impact studies are likely to favor treatments that reduce the annual episode of care, NovoSeven will need to explain its value in the emergency and perioperative setting to maintain its market position.

It is likely that NovoSeven will benefit from incremental demand due to bleeds associated with factor inhibitors during the 2025-2027 time period. Maintaining a leading market position will require NovoSeven to defend its

Strategic Growth Opportunities in the Eptacog Alfa (rFVIIa) Market

Eptacog alfa (rFVIIa) has significant potential to grow the market as bleeding management improves, protocols for controlling bleeding become more strict, and as additional market data outside of hemophilia becomes available. According to Lucintel, between 2024 and 2026, the market will be characterized by the adoption of rFVIIa for rare indications, or as needed, based upon the value rather than the volume of bleeding.

• Unmet Need for Treatment of Rare Bleeding Disorders: There are likely patients with other rare bleeding disorders such as congenital Factor VII deficiency and Glanzmann Thrombasthenia, who have not been diagnosed, especially if they do not have access to specialized centers. Novo Nordisk reported that in 2024, their sales for NovoSeven (rFVIIa) were DKK 7.6 billion. It is expected that better awareness and/or access to specialized care will increase the diagnosis of patients with rare bleeding disorders in the next 3 to 5 years.
• Improvement in Hospital Protocols: Several hospitals have policies to prevent and control bleeding in inhibitor patients. In a 2025 report, it was stated that rFVIIa was effective in 80% of the patients with congenital hemophilia. Use of hospital policies to manage bleeding in rFVIIa inhibitor patients will foster the use of the product for bleeding management.
• Opportunity in Emerging Markets: The use of rFVIIa in the treatment of bleeding in patients with hemophilia is largely restricted to high-income countries. The 2024 report of the World Federation of Hemophilia stated that 147 countries have hemophilia treatment centers. It is expected that local support and training will increase the availability of rFVIIa in the other 100 countries.
• Precision Dosing: Developments in pharmacology and IT have led to the implementation of several tools for precision dosing. These include software to analyze pharmacokinetics, electronic dosing pathways, and point-of-care coagulation testing. A study completed in 2025 (January 2025) evaluated the use of these tools at 12 different hospitals. The tools that allow hospitals to optimize dosing based on patient outcomes and costs are likely to be adopted.
• Alternative Reimbursement Models: Traditional reimbursement models that are based on the sale of a product will soon no longer enable manufacturers to recoup their costs. To remain viable, manufacturers will have to reinvent their businesses to include nurse education, case management and similar activities. A 2025 analysis by one of the major payers (October 2025) showed that costs associated with major bleeds at hospitals was in excess of $100,000. It is anticipated that manufactures will bundle their services to achieve premium prices.

Manufacturers that continue to thrive will be those that successfully reformulate their business models to combine services, diagnostic and other products. Through such integration, they can encourage and help healthcare systems to provide specialist bleeding services.

Eptacog Alfa (rFVIIa) Market Drivers and Challenges

The market for eptacog alfa (rfviia) is influenced by various technologies, economies, and rationales. Safety concerns and high cost limit market growth. Lucintel's view is that in the near term, market trend will be influenced by innovation and investment in the health care and related sectors, as well as development of products in specific areas.

The factors responsible for driving this market include:

• Need for Improved Control of Bleeds: Eptacog alfa has potential to control bleeds in patients with inhibitors to replacement therapies, including some patients with hemophilia A and B. Evidence from the use of bypassing agents in January 2025 demonstrated the need for and the potential of bypassing agents in the management of patients with inhibitors. Eptacog alfa is expected to fulfill this need over the next 3-5 years.
• Increased Diagnosis of Rare Diseases: Improved and specialized diagnostic services and awareness have enhanced the identification of patients with rare bleeding disorders including acquired hemophilia. In March 2025, several countries initiated or expanded similar programs. It is expected that during the next 3-5 years, increased rare disease diagnosis will result in enhanced identification of patients with rare bleeding disorders.
• Improvements in Recombinant Protein Technology: Enhancements in the technology that allows for the production of recombinant proteins have the potential to simplify and improve various aspects of the manufacturing, storage, and delivery of biopharmaceuticals. The improvements may help facilitate the rapid and widespread adoption of novel therapies. The clinical development of next-generation hemostatic therapies, which began in June 2025, is expected to positively impact the market in the next three to five years.
• Positive Clinical and Regulatory Environment: Continued interest and focus by regulators has provided clarity to the clinical community regarding the use of bypassing agents. Recommendations issued by hematology professionals in February 2025 regarding the use of rFVIIa further underscored the regulatory and clinical interest in treating inhibitor-related bleeding. Such recommendations are likely to increase demand for bypassing agents in the next three to five years.
• Expanding Healthcare Infrastructure: Increased emphasis on improving hemostasis and blood coagulation services further enhances the availability of specialized hemostatic products. The establishment of multidisciplinary bleeding disorder centers in September 2025, is expected to benefit the market in the next three to five years, by improving the safety of product use, and ensuring optimal service for patients.

The challenges facing this market include:

• Thromboembolic Safety: Use of eptacog alfa may increase thromboembolic events, especially in elderly patients and/or patients with cardiovascular disease. Intensive treatment may also increase the thromboembolic risk. In April 2025, the EMA provided an update on the Pharmacovigilance of potent hemostatic drugs and continued to evaluate thromboembolic events. This will create a three to-five-year demand for improved patient safety, including the choice of a lower dose. If safe and effective, alternative treatments may be used.
• Price: The high cost of recombinant biologics is due to the complexity of their production and the need for strict quality control. Many of these drugs require cold chain and/or hospital-based administration. In October 2025, payers restricted access to high cost biologics. It is expected that price constraints would limit the market in the next three to five years, especially in developing countries. It is expected that evidence demonstrating use of the drug would lead to a decrease in hospitalization and improvements in other clinical outcomes would increase market acceptance.
• Alternative Hemophilia Therapies: Emicizumab, antifibrinolytics, and immune and gene therapies will also target the hemophilia market. July 2025 witnessed the publication of trial data for various non-factor and gene-based therapies. This increased the competitiveness in the hemophilia A and B markets. The next three to five years will determine the market share of currently available hemo-factor therapies. Eptacog Alfa will likely remain on the market, as it meets the current standard of care for treatment of bleeding episodes and for managing inhibitors.

From a commercial perspective, the demand for eptacog alfa will increase, due to the inadequate management of bleeding episodes caused by inhibitors. However, there will be limited market growth due to its high cost and lack of reimbursement. There are a number of limitations to using eptacog alfa, due to a lack of adequate clinical and hemostatic experience, which will remain until further manufacturing and technological advances are made. Over the next three to five years, continued focus will be on treatment of bleeding episodes in specialized and emergent settings.

List of Eptacog Alfa (rFVIIa) Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies eptacog alfa (rfviia) market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eptacog alfa (rfviia) market companies profiled in this report include-

• Novo Nordisk
• LFB SA
• GENERIUM
• AryoGen Pharmed
• Chia Tai Tianqing Pharmaceutical Group

Eptacog Alfa (rFVIIa) Market by Segment

The study includes a forecast for the global eptacog alfa (rfviia) market by type, application, and region.

Eptacog Alfa (rFVIIa) Market by Type [Value ($B) from 2019 to 2035]:

• Prefilled Syringe
• Vial

Eptacog Alfa (rFVIIa) Market by Application [Value ($B) from 2019 to 2035]:

• Congenital Hemophilia
• Acquired Hemophilia
• Others

Eptacog Alfa (rFVIIa) Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Eptacog Alfa (rFVIIa) Market

The 2025-2027 eptacog alfa (rfviia) industry scenario will see more stringent hemophilia A treatment guidelines, continue to test manufacturers' resiliency and first-mover advantages, and increase regulatory scrutiny. Based on the latest Lucintel report, by 2027, the industry will be dominated by manufacturers that have established recombinant capacity and strategic partnerships with hospitals.

• United States: Novo Nordisk will continue to supply NovoSeven RT. The FDA will continue to regulate bypassing agents and require sponsors to perform post-marketing safety and assess pharmacovigilance. In 2027, the system will likely favor bypassing agents manufacturers that have contracts with a larger number of hospitals.
• China: The China National Medical Products Administration continues to strengthen the national review and centralized procurement of recombinant products. Novo Nordisk announced in 2025 that NovoSeven is marketed in 80 countries. Given the centralized procurement of recombinant products, it is likely that local Chinese manufacturers will gain and maintain market share of rfviia.
• Germany: Germany will continue to follow the standards of the European Medicines Agency and the AMNOG reimbursement process. NovoSeven RT will continue to be available through the haemophilia-care network. In 2025, the Commission's guidelines stipulated that documented measures relating to the quality and end-to-end traceability of biological medicinal products will apply. This is expected to lead to a more precise and consistent manufacture of biological medicinal products. As a result, the need for reimbursement dossiers will increase.
• India: The Central Drugs Standard Control Organisation (CDSCO) has been amending the regulations to enhance oversight of biologics. Availability of bypassing agents through public health facilities, in conjunction with haemophilia societies, has improved access. Price control of scheduled medicines by the National Pharmaceutical Pricing Authority continued in 2025. This will foster an affordable and reliable supply, more so if cold-chain logistics can be managed.
• Japan: The Pharmaceuticals and Medical Devices Agency (PMDA) will continue to follow its rigorous review process. The national health insurance system will determine reimbursement. From April 2025, a new Medical Fee Schedule will be implemented. This shows that the Japanese government will continue to have a central role in setting prices and determining utilization of medicinal products.

Features of the Global Eptacog Alfa (rFVIIa) Market

• Market Size Estimates: eptacog alfa (rfviia) market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: eptacog alfa (rfviia) market size by type, application, and region in terms of value ($B).
• Regional Analysis: eptacog alfa (rfviia) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the eptacog alfa (rfviia) market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eptacog alfa (rfviia) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the eptacog alfa (rfviia) market by type (prefilled syringe and vial), application (congenital hemophilia, acquired hemophilia, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?